BRAVECTO- fluralaner solution

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

FLURALANER (UNII: WSH8393RM5) (FLURALANER - UNII:WSH8393RM5)

Available from:

Merck Sharp & Dohme Corp.

Administration route:

TOPICAL

Prescription type:

PRESCRIPTION

Therapeutic indications:

Bravecto kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis ) and the treatment and control of Ixodes scapularis (black-legged tick) and Haemaphysalis longicornis (Asian longhorned tick) infestations for 12 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pounds or greater. Bravecto is also indicated for the treatment and control of Dermacentor variabilis (American dog tick) infestations for 8 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pounds or greater. There are no known contraindications for the use of the product.

Product summary:

Bravecto is available in three strengths for use in cats (112.5, 250, and 500 mg fluralaner per tube). Each tube is packaged individually in a pouch. Product may be supplied in 1 or 2 tubes per carton.

Authorization status:

New Animal Drug Application

Summary of Product characteristics

                                BRAVECTO- FLURALANER SOLUTION
MERCK SHARP & DOHME CORP.
----------
BRAVECTO
(FLURALANER TOPICAL SOLUTION)
FOR CATS
CAUTION:
Federal (USA) law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION:
Each tube is formulated to provide a minimum dose of 18.2 mg/lb (40
mg/kg) body
weight. Each milliliter contains 280 mg of fluralaner.
The chemical name of fluralaner is
(±)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-
dihydroisoxazol-3-yl]-2-methyl-_N_-[2-oxo-2-(2,2,2 -
trifluoroethylamino)ethyl]benzamide.
Inactive ingredients: dimethylacetamide, glycofurol, diethyltoluamide,
acetone
INDICATIONS:
Bravecto kills adult fleas and is indicated for the treatment and
prevention of flea
infestations (_Ctenocephalides felis_) and the treatment and control
of _Ixodes scapularis_
(black-legged tick) and _Haemaphysalis longicornis_ (Asian longhorned
tick) infestations for
12 weeks in cats and kittens 6 months of age and older, and weighing
2.6 pounds or
greater.
Bravecto is also indicated for the treatment and control of
_Dermacentor variabilis_
(American dog tick) infestations for 8 weeks in cats and kittens 6
months of age and
older, and weighing 2.6 pounds or greater.
DOSAGE AND ADMINISTRATION:
Bravecto should be administered topically as a single dose every 12
weeks according to
the DOSAGE SCHEDULE below to provide a minimum dose of 18.2 mg/lb (40
mg/kg)
body weight.
Bravecto may be administered every 8 weeks in case of potential
exposure to
_Dermacentor variabilis_ ticks (see EFFECTIVENESS).
DOSAGE SCHEDULE:
BODY WEIGHT
RANGES (LB)
FLURALANER
CONTENT
(MG/TUBE)
TUBES
ADMINISTERED
2.6 – 6.2
112.5
One
>6.2 – 13.8
250
One
®
*
*
>13.8 – 27.5
500
One
A veterinarian or veterinary technician should demonstrate or instruct
the pet owner
regarding the appropriate technique for applying Bravecto topically to
cats prior to first
use.
STEP 1: Immediately before use, open the pouch and remove the tube.
Put on gloves.
Hold the tube at the crimped end with the cap in an upright position
(tip up)
                                
                                Read the complete document
                                
                            

Search alerts related to this product